Hrt Financial LP Greenwich Life Sciences, Inc. Transaction History

Hrt Financial LP

$15.6 Billion
Q1 2024

A detailed history of Hrt Financial LP transactions in Greenwich Life Sciences, Inc. stock. As of the latest transaction made, Hrt Financial LP holds 15,165 shares of GLSI stock, worth $253,407. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,165

Holding current value

$253,407

% of portfolio

0.0%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$8.31 - $20.32 $126,021 - $308,152	15,165 New	15,165 $302,000
Q2 2023 Aug 11, 2023	SELL	$9.58 - $13.2 $81,142 - $111,804	-8,470 Reduced 45.52%	10,136 $97,000
Q1 2023 May 12, 2023	BUY	$12.12 - $20.8 $225,504 - $387,004	18,606 New	18,606 $256,000
Q3 2022 Nov 14, 2022	BUY	$7.81 - $12.02 $93,946 - $144,588	12,029 New	12,029 $109,000
Q1 2022 May 16, 2022	SELL	$16.3 - $24.65 $260,327 - $393,685	-15,971 Closed	0 $0

Q4 2021 Feb 14, 2022	BUY	$21.76 - $39.43 $347,528 - $629,736	15,971 New	15,971 $388,000
Q2 2021 Aug 16, 2021	SELL	$31.24 - $53.6 $342,140 - $587,027	-10,952 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$22.37 - $39.98 $244,996 - $437,860	10,952 New	10,952 $373,000

Others Institutions Holding GLSI

# of Institutions

Shares Held

645K

Call Options Held

Put Options Held

Vanguard Group Inc Valley Forge, PA

223K
Shares

$3.73 Million
0.0% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

63.8K
Shares

$1.07 Million
0.0% of portfolio
Geode Capital Management, LLC Boston, MA

58.2K
Shares

$973,257
0.0% of portfolio
Black Rock Inc. New York, NY

56.5K
Shares

$943,429
0.0% of portfolio
Goldman Sachs Group Inc New York, NY

41.5K
Shares

$693,548
0.0% of portfolio

View Full List

About Greenwich LifeSciences, Inc.

Ticker GLSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,848,200
Market Cap $215M
Description
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who ha...

More about GLSI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.

Account